Inoperable RCC: stereotactic ablative body radiotherapy shows promise

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Stereotactic ablative body radiotherapy (SABR) delivered encouraging cancer control, functional preservation and early survival outcomes in patients with small and large primary inoperable renal cell carcinoma (RCC). 
  • Treatment was well tolerated. 

Why this matters

  • Age and ...